Cargando…

Prognostic molecular markers in early breast cancer

A multitude of molecules involved in breast cancer biology have been studied as potential prognostic markers. In the present review we discuss the role of established molecular markers, as well as potential applications of emerging new technologies. Those molecules used routinely to make treatment d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esteva, Francisco J, Hortobagyi, Gabriel N
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400674/ https://www.ncbi.nlm.nih.gov/pubmed/15084231 http://dx.doi.org/10.1186/bcr777

Ejemplares similares

Inflammatory breast cancer: Clinical progress and the main problems that must be addressed
por: Giordano, Sharon H, et al.
Publicado: (2003)

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
por: Hortobagyi, Gabriel N.
Publicado: (2018)

Identification of early molecular markers for breast cancer
por: Kretschmer, Céline, et al.
Publicado: (2011)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma
por: Zagouri, Flora, et al.
Publicado: (2007)

A new paradigm for classifying and treating HER2‐positive breast cancer
por: He, Xuexin, et al.
Publicado: (2023)

Novel Molecular Markers for Breast Cancer
por: Inoue, Kazushi, et al.
Publicado: (2016)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
por: Pavicevic, Sandra, et al.
Publicado: (2022)

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer
por: Rose-James, Alphy, et al.
Publicado: (2012)

Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
por: Taneja, Pankaj, et al.
Publicado: (2010)

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
por: Giuliano, Mario, et al.
Publicado: (2011)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Molecular biology of breast cancer metastasis Molecular expression of vascular markers by aggressive breast cancer cells
por: Hendrix, Mary JC, et al.
Publicado: (2000)

Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors
por: Roy, David M, et al.
Publicado: (2014)

Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer
por: Hobbs, Evthokia A., et al.
Publicado: (2022)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Ki-67 as a prognostic marker according to breast cancer molecular subtype
por: Soliman, Nahed A., et al.
Publicado: (2016)

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
por: Jin, Quanri, et al.
Publicado: (2010)

Colorectal Cancer Screening Methods and Molecular Markers for Early Detection
por: Wu, Ziwei, et al.
Publicado: (2020)

Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
por: Banin Hirata, Bruna Karina, et al.
Publicado: (2014)

The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling
por: Verret, Benjamin, et al.
Publicado: (2022)

CXC ELR-Positive Chemokines as Diagnostic and Prognostic Markers for Breast Cancer Patients
por: Motyka, Joanna, et al.
Publicado: (2023)

Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review
por: Hoogland, A. Marije, et al.
Publicado: (2014)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer
por: Katayama, Hiroyuki, et al.
Publicado: (2019)

Breast cancer prognostic classification in the molecular era: the role of histological grade
por: Rakha, Emad A, et al.
Publicado: (2010)

RECK is not an independent prognostic marker for breast cancer
por: Gomes, Luciana R., et al.
Publicado: (2015)

An assessment of prognostic immunity markers in breast cancer
por: Yang, Benlong, et al.
Publicado: (2018)

The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy
por: Scioli, Maria Giovanna, et al.
Publicado: (2019)

The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer
por: Zhang, Wei, et al.
Publicado: (2011)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

The prognostic role of tumor size in early breast cancer in the era of molecular biology
por: Kasangian, Anaid Anna, et al.
Publicado: (2017)

Prognostic value of molecular markers and cytogenetic alterations that characterize breast cancer precursor lesions (Review)
por: DI BONITO, MAURIZIO, et al.
Publicado: (2013)

Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
por: Piskór, Barbara Maria, et al.
Publicado: (2020)

Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value
por: Fabisiewicz, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8k2msci4skjutdq8flpibs80d7